Oral delivery of xenon for cardiovascular protection.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
01 Oct 2019
Historique:
received: 02 04 2019
accepted: 13 09 2019
entrez: 3 10 2019
pubmed: 3 10 2019
medline: 28 10 2020
Statut: epublish

Résumé

Cardiac hypertrophy often causes impairment of cardiac function. Xenon (Xe), a naturally occurring noble gas, is known to provide neurological and myocardial protection without side effects. The conventional method of Xe delivery by inhalation is not feasible on a chronic basis. We have developed an orally deliverable, effective Xe formulation for long-term administration. We employed 2-hydroxypropyl)-β-cyclodextrin (HPCD), which was dissolved in water to increase the Xe concentration in solution. The beneficial effects of long-term oral administration of Xe-enriched solutions on cardiovascular function were evaluated in vivo. HPCD increased Xe solubility from 0.22 mM to 0.67 mM (3.8-fold). Aged ApoE knockout mice fed high-fat diet for 6 weeks developed hypertension, and myocardial hypertrophy with impaired cardiac function. Oral Xe prevented this ischemic damage, preserving normal blood pressure, while maintaining normal left ventricular mass and wall thickness. This novel formulation allows for gastrointestinal delivery and cardiovascular stabilization.

Identifiants

pubmed: 31575906
doi: 10.1038/s41598-019-50515-3
pii: 10.1038/s41598-019-50515-3
pmc: PMC6773773
doi:

Substances chimiques

Apolipoproteins E 0
Cardiotonic Agents 0
Solutions 0
2-Hydroxypropyl-beta-cyclodextrin 1I96OHX6EK
Xenon 3H3U766W84

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

14035

Références

Can J Anaesth. 2002 Nov;49(9):942-5
pubmed: 12419721
AAPS PharmSciTech. 2011 Mar;12(1):279-86
pubmed: 21240574
Anesth Analg. 2008 Sep;107(3):769-75
pubmed: 18713881
Acta Anaesthesiol Scand. 2005 Jul;49(6):743-9
pubmed: 15954952
Circulation. 2012 Oct 16;126(16):2020-35
pubmed: 22923432
Am J Physiol Endocrinol Metab. 2012 Mar 1;302(5):E481-95
pubmed: 22167522
Crit Care Med. 2008 Aug;36(8):2477-9
pubmed: 18664813
Mol Pharmacol. 2008 Nov;74(5):1223-33
pubmed: 18687808
Anesthesiology. 2011 Jun;114(6):1373-9
pubmed: 21403515
Best Pract Res Clin Anaesthesiol. 2005 Sep;19(3):461-74
pubmed: 16013694
Circ Res. 2014 Apr 25;114(9):1377-88
pubmed: 24557880
J Vet Med Sci. 2012 Dec;74(12):1651-5
pubmed: 22814088
Clin Nutr. 2005 Jun;24(3):407-14
pubmed: 15896427
Pharmacol Ther. 2010 Dec;128(3):499-508
pubmed: 20826180
Am J Physiol Heart Circ Physiol. 2012 Oct 15;303(8):H967-78
pubmed: 22904156
Arterioscler Thromb Vasc Biol. 2012 Aug;32(8):1902-9
pubmed: 22556331
J Cereb Blood Flow Metab. 2006 Feb;26(2):199-208
pubmed: 16034370
Acta Anaesthesiol Scand. 2010 Apr;54(4):470-8
pubmed: 19839950
Alcohol. 2013 Feb;47(1):27-30
pubmed: 23084029
J Biol Chem. 2009 Oct 9;284(41):28128-36
pubmed: 19666465
Eur J Med Res. 2001 Nov 20;6(11):488-92
pubmed: 11726308
Am J Transplant. 2013 Aug;13(8):2006-18
pubmed: 23710625
Rapid Commun Mass Spectrom. 2017 Jan 15;31(1):1-8
pubmed: 27689777
Circulation. 2016 Jan 26;133(4):447-54
pubmed: 26811276
Anesthesiology. 2008 Feb;108(2):199-207
pubmed: 18212564
FASEB J. 2013 Dec;27(12):4822-33
pubmed: 23934278
Am J Physiol. 1982 Dec;243(6):H941-7
pubmed: 6216817
Eur J Med Res. 2002 Mar 28;7(3):109-16
pubmed: 11953281
Arterioscler Thromb. 1994 Jan;14(1):133-40
pubmed: 8274468
Hypertension. 1995 May;25(5):1111-5
pubmed: 7737724
Circulation. 2012 Oct 9;126(15):1828-37
pubmed: 22972900
Arterioscler Thromb Vasc Biol. 2007 Jul;27(7):1493-5
pubmed: 17581829
Circulation. 2008 May 20;117(20):2626-36
pubmed: 18474817
J Am Soc Nephrol. 2009 Apr;20(4):713-20
pubmed: 19144758
J Biol Chem. 2009 May 8;284(19):12691-700
pubmed: 19286667
Am J Med. 1978 Jul;65(1):106-25
pubmed: 99030
J Biomed Sci. 2012 Feb 13;19:22
pubmed: 22330242
Circ Res. 2008 Nov 21;103(11):1259-69
pubmed: 18849323
Arterioscler Thromb. 1994 Jan;14(1):141-7
pubmed: 8274470
Am J Physiol Heart Circ Physiol. 2009 May;296(5):H1281-8
pubmed: 19252084
Cardiovasc Res. 2007 Jan 1;73(1):8-9
pubmed: 17156766
Am J Cardiol. 1982 Jul;50(1):129-35
pubmed: 7090995

Auteurs

Xing Yin (X)

Division of Cardiovascular Medicine, Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, Texas, 77030, USA.

Melanie R Moody (MR)

Division of Cardiovascular Medicine, Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, Texas, 77030, USA.

Valeria Hebert (V)

Department of Comparative Biomedical Science, School of Veterinary Medicine, Louisiana State University Health Science Center, Shreveport, Louisiana, 71103, USA.

Melvin E Klegerman (ME)

Division of Cardiovascular Medicine, Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, Texas, 77030, USA.

Yong-Jian Geng (YJ)

Division of Cardiovascular Medicine, Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, Texas, 77030, USA.

Tammy R Dugas (TR)

Department of Comparative Biomedical Science, School of Veterinary Medicine, Louisiana State University Health Science Center, Shreveport, Louisiana, 71103, USA.

David D McPherson (DD)

Division of Cardiovascular Medicine, Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, Texas, 77030, USA.

Hyunggun Kim (H)

Division of Cardiovascular Medicine, Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, Texas, 77030, USA. hkim.bme@skku.edu.
Department of Biomechatronic Engineering, Sungkyunkwan University, Suwon, Gyeonggi, 16419, Korea. hkim.bme@skku.edu.

Shao-Ling Huang (SL)

Division of Cardiovascular Medicine, Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, Texas, 77030, USA. Shaoling.Huang@uth.tmc.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH